Pharmaceutical company Amneal Pharmaceuticals Inc (NYSE:AMRX) reported on Friday the receipt of the Abbreviated New Drug Application (ANDA) approval from the US Food and Drug Administration (FDA) for the generic Fluphenazine Hydrochloride Tablets USP in 1mg, 2.5mg, 5mg and 10mg for treatment of schizophrenia.
The company added that the Fluphenazine Hydrochloride is the generic version of Prolixin for treatment of schizophrenia.
Effective immediately, the company has initiated commercialization activities of generic Fluphenazine Hydrochloride across all dosages.
In conjunction, the US annual sales for Fluphenazine Hydrochloride Tablets for the 12 months ended May 2020 were approximately USD143m, according to IQVIA, a leading healthcare data and analytics provider.
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US